|
|
|
|
|
Bupivacaine
drug data and news
Bupivacaine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Bupivacaine | ||
| Brand Names/Synonyms | Anekain; Bloqueina; Bupivacaine; Bupivacaine Hcl; Bupivacaine Hcl Kit; Bupivacine Hcl Preservative Free; Bupivan; Carbostesin; Cbupivacaine; Chirocaine; D,L-Bupivacaine; Dl-Bupivacaine; LAC-43; Marcaina; Marcaine; Marcaine Hcl; Marcaine Spinal; Sensorcaine; Sensorcaine Forte; Sensorcaine-Mpf Spinal | ||
| Indication | For the production of local or regional anesthesia or analgesia for surgery. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Bupivacaine, a local amino amide-type anesthetic agent, is indicated for the production of local or regional anesthesia or analgesia for surgery, for oral surgery procedures, for diagnostic and therapeutic procedures, and for obstetrical procedures. Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination and conduction velocity of affected nerve fibers. | ||
| Mechanism Of Action | Local anesthetics produce anesthesia by inhibiting excitation of nerve endings or by blocking conduction in peripheral nerves. Bupivicaine reversibly binds to and inactivates sodium channels (Voltage-gated sodium channel alpha subunit Nav1.8). Sodium influx through these channels is necessary for the depolarization of nerve cell membranes and subsequent propagation of impulses along the course of the nerve. When a nerve loses depolarization and capacity to propagate an impulse, the individual loses sensation in the area supplied by the nerve. The analgesic effects of Bupivicaine are thought to be due to its binding to the prostaglandin E2 receptors, subtype EP1 (PGE2EP1), which inhibits the production of prostaglandins, thereby reducing fever, inflammation, and hyperalgesia | ||
| Bupivacaine News (When available) |
Regulation of Intracellular Calcium by Bupivacaine Isomers in ... Feb 22, 2006 A Randomized Comparison of Programmed Intermittent Epidural Bolus ... Feb 21, 2006 Blurred Vision as the only Symptom of a Positive Epidural Test ... Feb 21, 2006 Continuous Epidural Block Versus Continuous Popliteal Nerve Block ... Feb 21, 2006 DURECT Corporation Reports Fourth Quarter and Year End 2005 ... Feb 8, 2006 Combined Spinal Epidural Causes Higher Level of Block than ... Feb 14, 2006 Pain In Horses Feb 4, 2006 SkyePharma Issues EGM Notice and Recommends Shareholders to Vote ... Feb 17, 2006 DURECT Corporation Reports Fourth Quarter and Year End 2005 ... Feb 8, 2006 Is the Interscalene Brachial Plexus Block the Best Approach? Feb 14, 2006 DURECT to Expand Clinical Program to Additional Surgical ... Jan 26, 2006 The Effects of Local Anesthetics on Bile Flow, Potassium ... Jan 29, 2006 Local Anesthetics Suppress Nerve Growth Factor-Mediated Neurite ... Jan 29, 2006 Pain In Horses Feb 4, 2006 SkyePharma Announces Appointment of New Chairman and Outcome of ... Feb 2, 2006 Epidural Won't Lessen Long-Term Shingles Pain Jan 19, 2006 Shingles, Epidural Injection Does Not Reduce Long-term Pain Jan 22, 2006 Perioperative Nimodipine and Postoperative Analgesia Jan 29, 2006 Epidural Steroid Injection Not Useful for Chronic Shingles Pain Jan 19, 2006 Injection Doesn't end Shingles Pain Jan 19, 2006 Can’t Blame Ropivacaine Sep 30, 2005 DURECT Corporation Announces Completion of Dosing in Cohort 3 of ... Sep 19, 2005 DURECT to Present Preliminary Phase II Clinical Data for Cohort 3 ... Sep 21, 2005 Can’t Blame Ropivacaine Sep 30, 2005 The Anticatabolic Effect of Neuraxial Blockade After Hip Surgery Sep 30, 2005 Plasma Bupivacaine Concentrations Are Too Low to Explain Reduced ... Aug 22, 2005 Plasma Bupivacaine Concentrations Are Too Low to Explain Reduced ... Aug 22, 2005 The Myocardial and Vascular Effects of Bupivacaine ... Aug 22, 2005 Determining the Plasma Concentration of Ketamine That Enhances ... Aug 22, 2005 The Effects of Femoral Nerve Blockade in Conjunction with Epidural ... Aug 22, 2005 Spinal Versus Epidural Anesthesia for Cesarean Delivery in Severe ... Aug 22, 2005 Spinal Anesthesia-Induced Hypotension: A Risk Comparison Between ... Aug 22, 2005 Ultrasound-Guided Infraclavicular Versus Supraclavicular Block Aug 22, 2005 Continuous Intra- and Postoperative Thoracic Epidural Analgesia ... Aug 22, 2005 Ketamine Sedation During Spinal Anesthesia for Arthroscopic Knee ... Aug 22, 2005 Reduction in Requirement of Propofol During Combined Epidural ... Jul 21, 2005 The Comparative Neurotoxicity of Intrathecal Lidocaine and ... Jul 21, 2005 The Long Term Myotoxic Effects of Bupivacaine and Ropivacaine ... Jul 21, 2005 Improved pain management outcomes with continuous infusion of a ... Aug 5, 2005 DURECT Announces Start of Dosing in Cohort 3 of Its Phase II Study ... Jul 11, 2005 The Short-Lasting Analgesia and Long-Term Antihyperalgesic Effect ... Jul 21, 2005 DURECT Corporation Announces Second Quarter 2005 Financial Results Jul 22, 2005 The Influence of Lumbosacral Cerebrospinal Fluid Volume on Extent ... Jul 21, 2005 Intrathecal Morphine for Postpartum Bilateral Tubal Ligation Jul 21, 2005 A Novel Technique for Experimental Stellate Ganglion Block in Rats Jul 21, 2005 Anesthetic Management Using Echocardiography for Surgery of Lower ... Jul 21, 2005 Nerve Stimulation for Regional Anesthesia of the Face: Use of the ... Jul 21, 2005 | ||
| Dosage Forms | SOLUTION | ||
| Drug_Category | Anesthetics; Local Anesthetics; ATC:N01BB01; ATC:N01BB10 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Bupivacaine: The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations in which concurrent therapy is necessary, careful patient monitoring is essential. Concurrent administration of vasopressor drugs and of ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 1-butyl-N-(2,6-dimethylphenyl)-piperidine-2-carboxamide | ||
| Chemical Formula | C18H28N2O | ||
| Molecular Weight | 288.428 g/mol | ||
| Smiles String | CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C | ||
| Melting Point | 107-108 °C | ||
| Water Solubility | 2400 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 3.987 | ||
| Isoelectric Point | 8.1 | ||
| Biotransformation | Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. | ||
| Half Life | 2.7 hours | ||
| Protein Binding [%] | 95% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Bupivacaine.html http://www.rxlist.com/cgi/generic2/bupivacaine.htm http://www.pharmgkb.org/views/index.jsp?objId= | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00247 | ||
| CAS Registry Number | 2180-92-9 | ||
| KEGG Compound ID | C07529 | ||
| PubChem ID | SID:9732 | ||
| PharmGKB ID | PA448683 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2165414 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |